Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Open and Percutaneous Fixation of Traumatic Sacral Fracture-Dislocation with Spinopelvic Dissociation: Two Adolescent Cases and a Systematic Literature Review.

Journal of clinical medicine·2026

Same author

Intramedullary Nailing Versus Modular Megaprosthesis in Pathological Humeral Fractures: A 10-Year Retrospective Comparative Study.

Diseases (Basel, Switzerland)·2026

Same author

Triage Assessment of Lateral Ankle Sprain Surgical Risk (TALAR Score): Using Early Red Flags to Predict the Failure of Conservative Management.

Journal of functional morphology and kinesiology·2026

Same author

Lateral Femoral Neck and Peritrochanteric Fractures: Anatomical Classifications and Pre-Operative Reduction Techniques-A Narrative Review.

Journal of functional morphology and kinesiology·2026

Same author

Patient perspectives on humeral lengthening in achondroplasia: association between treatment timing and acceptance.

European journal of orthopaedic surgery & traumatology : orthopedie traumatologie·2026

Same author

The use of debridement, antibiotic pearls, and implant retention (DAPRI) in the management of acute periprosthetic joint infections: a systematic review.

Journal of bone and joint infection·2026

Search research articles

Related Experiment Video

Updated: Jan 13, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Osteosarcoma: A Comprehensive Morphological and Molecular Review with Prognostic Implications.

Alessandro El Motassime^1,2, Raffaele Vitiello^1,2, Rocco Maria Comodo^1,2,3

¹Department of Orthopedics and Geriatric Sciences, Catholic University of the Sacred Heart, 00168 Rome, Italy.

|October 29, 2025

Summary

Osteosarcoma (OS) survival needs improvement. This review integrates pathology, molecular, and immune data to guide precision medicine, focusing on new biomarkers and targeted therapies for better patient outcomes.

Keywords:

bone tumor immune biomarkers molecular pathways osteosarcoma tumor microenvironment

More Related Videos

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Related Experiment Videos

Last Updated: Jan 13, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Area of Science:

Oncology
Immunology
Genetics

Background:

Osteosarcoma (OS) is the most common primary bone cancer in adolescents and young adults.
Current treatments offer limited survival rates for metastatic or recurrent OS, necessitating new strategies.

Purpose of the Study:

To provide a comprehensive understanding of OS biology for precision medicine.
To integrate histopathologic, molecular, and immune data for improved prognostic and therapeutic approaches.

Main Methods:

Review of histopathologic and radiographic features.
Analysis of the tumor microenvironment, including immune cells and checkpoints.
Evaluation of emerging molecular markers and dysregulated pathways (WNT/β-catenin, JAK/STAT).

Main Results:

Identification of key immune components (lymphocytes, macrophages) and their roles.
Assessment of molecular markers (immune risk signatures, ctDNA, gasdermin D) for prognostic value.
Examination of pathway dysregulation in metastasis, chemoresistance, and immune evasion.

Conclusions:

Integrated biomarker assessment can refine patient stratification in OS.
Bridging histopathology, immunogenomics, and translational research is crucial for individualized treatment strategies.